Regeneron Pharmaceuticals (REGN) Gross Margin (2009 - 2026)

Regeneron Pharmaceuticals' Gross Margin history runs 18 years deep, the most recent figure standing at 91.79% for Q1 2026.

• In Q1 2026, Gross Margin fell 165.0% year-over-year to 91.79%; the TTM figure through Mar 2026 stood at 93.63% (up 81.0% YoY), while the FY2025 annual figure was 93.31%, up 96.0% from the prior year.
• Gross Margin was 91.79% for Q1 2026 at Regeneron Pharmaceuticals, down from 96.45% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 96.45% in Q4 2025 to a low of 314.6% in Q1 2022.
• Historically, Gross Margin has averaged 55.79% across 5 years, with a median of 93.44% in 2025.
• The sharpest annual moves came in 2022 and 2023: Gross Margin slumped 40736 bps in 2022, then surged 40672 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 138.4% in 2022, then jumped by 168 bps to 93.88% in 2023, then declined by 3 bps to 91.38% in 2024, then gained by 6 bps to 96.45% in 2025, then slipped by 5 bps to 91.79% in 2026.
• The last three Gross Margin figures came in at 91.79% (Q1 2026), 96.45% (Q4 2025), and 93.59% (Q3 2025), per Business Quant data.